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Abstract
Our understanding of the diversity of cells that escape the primary tumor and seed micrometastases remains
rudimentary, and approaches for studying circulating and disseminated tumor cells have been limited by low
throughput and sensitivity, reliance on single parameter sorting, and a focus on enumeration rather than
phenotypic and genetic characterization. Here, we utilize a highly sensitive microfluidic and dielectrophoretic
approach for the isolation and genetic analysis of individual tumor cells. We employed fluorescence labeling to
isolate 208 single cells from spiking experiments conducted with 11 cell lines, including 8 neuroblastoma cell
lines, and achieved a capture sensitivity of 1 tumor cell per 106 white blood cells (WBCs). Sample fixation or
freezing had no detectable effect on cell capture. Point mutations were accurately detected in the whole
genome amplification product of captured single tumor cells but not in negative control WBCs. We applied
this approach to capture 144 single tumor cells from 10 bone marrow samples of patients suffering from
neuroblastoma. In this pediatric malignancy, high-risk patients often exhibit wide-spread hematogenous
metastasis, but access to primary tumor can be difficult or impossible. Here, we used flow-based sorting to
pre-enrich samples with tumor involvement below 0.02%. For all patients for whom a mutation in the
Anaplastic Lymphoma Kinase gene had already been detected in their primary tumor, the same mutation was
detected in single cells from their marrow. These findings demonstrate a novel, non-invasive, and adaptable
method for the capture and genetic analysis of single tumor cells from cancer patients.
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Our understanding of the diversity of cells that escape the primary tumor and seed
micrometastases remains rudimentary, and approaches for studying circulating and dis-
seminated tumor cells have been limited by low throughput and sensitivity, reliance on
single parameter sorting, and a focus on enumeration rather than phenotypic and genetic
characterization. Here, we utilize a highly sensitive microfluidic and dielectrophoretic
approach for the isolation and genetic analysis of individual tumor cells. We employed
fluorescence labeling to isolate 208 single cells from spiking experiments conducted with
11 cell lines, including 8 neuroblastoma cell lines, and achieved a capture sensitivity of
1 tumor cell per 106 white blood cells (WBCs). Sample fixation or freezing had no detectable
effect on cell capture. Point mutations were accurately detected in the whole genome
amplification product of captured single tumor cells but not in negative control WBCs. We
applied this approach to capture 144 single tumor cells from 10 bone marrow samples
of patients suffering from neuroblastoma. In this pediatric malignancy, high-risk patients
often exhibit wide-spread hematogenous metastasis, but access to primary tumor can be
difficult or impossible. Here, we used flow-based sorting to pre-enrich samples with tumor
involvement below 0.02%. For all patients for whom a mutation in the Anaplastic Lym-
phoma Kinase gene had already been detected in their primary tumor, the same mutation
was detected in single cells from their marrow. These findings demonstrate a novel, non-
invasive, and adaptable method for the capture and genetic analysis of single tumor cells
from cancer patients.
Keywords: neuroblastoma, disseminated tumor cell, circulating tumor cell, single cell capture, whole genome
amplification, targeted sequencing
INTRODUCTION
Metastatic cancer is almost uniformly lethal and occurs when cir-
culating or disseminated tumor cells (CTC/DTCs) engraft sites
distant from the primary tumor (1). Metastatic disease remains
a challenge not only to treat but also to study, as tumor sam-
ples in patients with advanced cancer are often difficult to obtain.
Lack of surgical access to tumor in this setting implies that prog-
nostic and treatment decisions must be based on primary tumor
attributes, often from a single time point, and in the absence of a
characterization of metastatic cells, despite known genomic varia-
tion between CTC/DTCs and primary tumor (2–4). Indeed, recent
studies of prostate (5), breast (6), and other cancers (7, 8) suggest
considerable cell to cell genomic heterogeneity within different
tumor biopsies from an individual patient, challenging the efforts
to monitor solid cancer heterogeneity. While CTCs from the blood
are often studied, tumor cells, which have disseminated to the mar-
row (DTCs), may also form a reservoir of cells that could seed
distant metastases (9), and are less well characterized. In addition,
the advent of newer targeted therapies mandates molecular assess-
ment of both the primary and circulating/disseminated tumor
to comprehensively determine target molecule expression. Thus,
accessing the circulating and disseminated tumor compartments
via serial blood draws and/or bone marrow biopsies provides
a non-invasive approach for studying the implications of het-
erogeneity, and fully realizing the benefits of targeted therapies.
Moreover, CTC/DTCs can theoretically be assayed as markers of
minimal residual disease, and, once isolated, can be probed for
molecular diagnostic and/or therapeutic response information.
Gaining fundamental knowledge about the cell to cell diversity of
cancer metastasis will be critical for understanding if therapeu-
tic targets identified in primary tumor tissue are relevant in the
metastatic cells, and a key driver for the development of rational
and effective early phase clinical trials for cancer patients.
Single cell capture has generally relied on labor-intensive,
low throughput techniques such as manual micromanipula-
tion of EpCAM- or cytokeratin-stained cells (3, 10) or in situ
hybridization-based analysis of tissue sections (11, 12). More
recent studies, however, hint at the wealth of clinically relevant
information to be gleaned from a more sensitive and higher
throughput approach to single cell analysis (6, 12, 13). However,
even with the use of technologies such as the FDA-approved
CellSearch system, the detection of tumor cells in the blood or
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marrow of patients has often been limited to bulk analysis of
EpCAM-positive tumor cells (14–17). While enumeration of these
cells can provide valuable prognostic information, genetic pro-
filing of CTC/DTCs can likely inform individualized treatment
decisions and guide selection of targeted therapies. To address this,
we have adopted the DEPArray microelectronics and microflu-
idics technology for individual tumor cell capture from pediatric
bone marrow samples. This platform, recently shown to be effec-
tive for the isolation of tumor cells from lung and breast cancer
patient blood samples (18, 19), utilizes dielectrophoresis (DEP)
to electronically trap and move individual cells, thereby provid-
ing a means to isolate rare cells from heterogeneous samples for
single cell analysis (20–22). Fluorescence-labeled cells are iso-
lated from complex biological samples based on expression of
single or multiple antigens that distinguish between tumor and
cells of hematopoietic origin, thus allowing for the capture of
non-epithelial tumors as well as EpCAM-negative tumor cells of
epithelial origin which have undergone epithelial to mesenchymal
transition (EMT).
To demonstrate the feasibility of a DEPArray-based approach
to DTC isolation and genetic analysis, we have focused on neurob-
lastoma, a childhood malignancy of the developing sympathetic
nervous system. Neuroblastoma patients present with wide-spread
hematogenous based metastases in over 50% of cases (23), and
tumor cells have been detected by immunocytologic approaches in
the marrow of 81% and the blood of 58% of stage 4 neuroblastoma
patients at diagnosis (24). Notable for its phenotypic variability
and widely divergent clinical courses, the disease accounts for
a disproportionate amount of childhood cancer morbidity and
mortality (25). Multiple groups have used RT-PCR-based detec-
tion of neuroblastoma specific transcripts to further demonstrate
that neuroblastoma is a systemic disease, and outcome is highly
correlated with circulating tumor burden, and/or failure to clear
disseminated cells (26–30). Recently introduced targeted therapies
for neuroblastoma patients include the small molecule inhibitor
Crizotinib, which targets the receptor tyrosine kinase Anaplas-
tic Lymphoma Kinase (ALK) and was well tolerated in a recent
Phase 1 dose-escalation trial (31). A randomized clinical trial of
an immunotherapeutic regimen, including the ch14.18 mono-
clonal antibody targeting the disialoganglioside GD2, resulted in
a dramatic increase in event-free survival from 46 to 66% (32).
However, despite these recent advances, most high-risk neuroblas-
toma patients die from their disease (23). Therefore, the frequency
of CTC/DTCs, the lack of EpCAM expression, the advent of tar-
geted therapies, and the urgent need for additional therapeutic
options for high risk patients make neuroblastoma an ideal dis-
ease in which to establish proof of principle for the capture and
molecular analysis of DTCs. In this study, we used cell line spiking
experiments to establish the sensitivity and specificity of single cell
isolation and targeted sequencing, and then applied this approach
to neuroblastoma patient bone marrow samples.
MATERIALS AND METHODS
PATIENT SAMPLES AND MONONUCLEAR CELL ISOLATION
Six de-identified neuroblastoma patient bone marrow samples
were obtained from subjects enrolled on Children’s Oncology
Group trial ADVL0912 (NCT00939770) (31). Written informed
consent from parents or guardians was obtained, and the insti-
tutional review boards of participating institutions approved
the protocol. Four additional de-identified and discarded bone
marrow samples were obtained from the Children’s Hospital of
Philadelphia; the use of these de-identified samples is not human
subjects’ research according to our Institutional Review Board,
thereby waiving the need for consent. Peripheral blood for spiking
experiments was obtained from normal donors after obtaining
written informed consent and using protocols approved by the
Institutional Review Board of the Hospital at the University of
Pennsylvania. Buffy coats from bone marrow were enriched by
Ficoll centrifugation (GE Healthcare Life Sciences, Piscataway, NJ,
USA). If cells were not immediately used for additional assays,
fixation was performed using Miltenyi Inside Fix (Miltenyi Biotec
Inc., Auburn, CA, USA).
CELL LINES AND SPIKING EXPERIMENTS
All cell lines were obtained from the Children’s Hospital of
Philadelphia cell line bank. The NB1643M cell line is a sub-clone
of NB1643, which is homozygous for the known ALK R1275Q
mutation. All cell lines were maintained in a 5% CO2 incuba-
tor at 37°C in complete RPMI (Invitrogen, Carlsbad, CA, USA).
Tumor cell identity was authenticated using AmpFLSTR Identi-
filer (Applied Biosystems, Grand Island, NY, USA) and all cell
lines were routinely mycoplasma tested. Adherent cell lines were
grown to 70–80% confluency before being used for spiking experi-
ments, then trypsin-treated for dissociation from the flask surface.
For spiking experiments, cell lines and white blood cells (WBCs)
were washed twice separately and counted. Cell lines were then
serially diluted into WBCs at the indicated ratios ranging from
a tumor:WBC ratio of 1:10 to 1:1,000,000. Spiked samples were
then fluorescently labeled and entered into the DEPArray (Sili-
con Biosystems, Bologna, Italy) workflow as described below and
depicted in Figure 1. Due to the 40,000 cell capacity of the DEPAr-
ray cartridge, pre-enrichment of the sample was first completed
on the FACSAria II (Becton Dickinson Franklin Lakes, NJ, USA)
prior to running on the DEPArray, if the tumor cell concentration
was below 1 in 5,000 WBCs (0.02%). At this tumor cell concen-
tration, a full cartridge containing 40,000 cells would be likely to
contain only 8 tumor cells, a number below which it would be
difficult to conduct meaningful downstream analysis. For most
experiments described here, FACSAria-based enrichment yielded
less than 40,000 total cells and, therefore, all enriched cells were
injected into a single DEPArray cartridge. For the two patient sam-
ples for which the number of enriched cells exceeded 40,000, the
FACSAria output was divided between two DEPArray cartridges.
ANTIBODIES AND FLOW CYTOMETRY
Flow cytometry was conducted using an Attune cytometer
(Life Technologies, Grand Island, NY, USA) and Venturi soft-
ware (Applied Cytometry, Dinnington, UK). Cells were analyzed
using isotype antibody controls, Violet/SYTOX (Life Technolo-
gies) to detect apoptotic cells, Hoechst 33342 nucleic acid stain
(Life Technologies), and monoclonal antibodies obtained from
BD Biosciences (BD340723 CD56-FITC, BD554272 14.18 GD2-
PE, BD347198 EpCAM-PE, BD347197 EpCAM-FITC, BD555997
EGFR-PE), Invitrogen (MHCD45054 CD45-APC, MHCD45014
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FIGURE 1 | Workflow for rare single cell isolation by DEPArray. Shown
are the steps for dielectrophoretic isolation and downstream genetic
analysis of single cells. Because the DEPArray cartridge has a capacity of
~40,000 cells, if the tumor cell concentration is below 0.02%,
pre-enrichment of the sample is first completed on the FACSAria.
CD45-FITC), and BioLegend (324406 HER-2-PE). Prior to
staining, all antibodies were prefiltered using Millipore (Billerica,
MA, USA) 0.65µm Ultrafree-MC centrifugal filter units.
ISOLATION OF SINGLE TUMOR CELLS BY DEPArray
Isolation of single cells from patient and spiked samples can be
a lengthy and complex process. In order to ensure that yield and
quality of isolated cells are not compromised, it is recommended
that the following steps be completed in as rapid succession as pos-
sible. Reagents and materials should be assembled ahead of time,
and all steps were followed precisely. As depicted in the flow chart
in Figure 1, whole blood or marrow samples were subjected to
Ficoll (GE Healthcare Life Sciences) centrifugation, and the post-
Ficoll suspension of cells processed live or, when necessary, fixed
for later analysis. Cells were counted, and then stained for the rel-
evant tumor antigen(s), as well as the negative control CD45. To
determine the tumor cell frequency of unenriched patient samples,
an aliquot of ~1 million total cells was analyzed by flow cytome-
try. The percentage of tumor cells was determined by calculating
the number of cells positively expressing the tumor antigen(s) of
interest but not CD45. As described above, pre-enrichment of the
sample was first completed on the BD FACSAria II prior to run-
ning on the DEPArray, if the tumor cell concentration was below
0.02%. Sorts were conducted using 70µm nozzles at 70 psi with
cells collected into a conical containing phosphate buffered saline
(PBS) and 2 mM ethylenediaminetetraacetic acid (EDTA). Prior
to loading into the DEPArray cartridge, cells were maintained in
a polypropylene conical to minimize cell loss during two subse-
quent washes. Cells were then resuspended in SB115 buffer (Silicon
Biosystems) if fixed or complete RPMI if cells were live, and 14µl
of sample and 800µl of buffer were loaded into the cartridge. Of
the 14µl of loaded sample, 9.26µl (or 66% of the total volume)
then filled the electrode-embedded chamber from which single
cells were selected, therefore, CTC/DTC yield was never expected
to approach 100%. The cartridge was then placed in the DEPArray
apparatus and non-uniform electrical fields applied. The system
does not require a priori thresholds, and, therefore, all events are
displayed in the Cell Browser scatter plot, and gating applied after
visual inspection of events. Individual or small groups of cells
were captured into 0.2 ml microtubes (Applied Biosystems). Fol-
lowing collection, each cell/tube was then washed once in PBS and
the supernatant carefully removed, leaving the cell(s) in approx-
imately 1µl of volume. Cells were then frozen at -20°C pending
downstream analysis.
SINGLE CELL WHOLE GENOME AMPLIFICATION, PCR, AND
SEQUENCING
The Ampli1 whole genome amplification (WGA) approach (Sil-
icon Biosystems) is based on adaptor-mediated PCR following
site-specific DNA digestion with all reactions performed in one
tube to avoid template loss and thus resulting in a library of highly
concentrated DNA fragments 0.2–2 kb in length. Given the minute
amounts of DNA being amplified and the risk of sequencing
results being influenced or compromised, routine lab habits and
techniques are likely incompatible with the generation of reliable
and accurate sequencing results from single cells. To address this,
procedures are described below in considerable detail and should
be followed precisely. In order to prevent carryover of amplified
DNA to single cell samples, once single cells were obtained in
individual microtubes by DEPArray, all downstream processing
was completed in two separated rooms: one dedicated to WGA
and the other to PCR. Each room contained its own PCR hood,
pipettes, racks, Veriti thermal cycler (LifeTech), freezer, and cen-
trifuge (VWR, Radnor, PA, USA). Access to these areas was only
permitted for single cell work and single-use gowns were worn
rather than lab coats to reduce the chance of cross-contamination.
After each experiment, all work areas were wiped down with DNA
AWAY (Molecular BioProducts, San Diego, CA, USA), followed
by 70% ethanol, and irradiated with UV light for at least 30 min
using standalone UV lamps (UVP). The Ampli1 WGA protocol
was used exactly as specified by the manufacturer. In brief, lysis
reaction mix was added to each sample and incubated at 42°C
overnight. Next, digestion reaction mix was added to the same
tube and incubated at 37°C for 3 h. Next, ligation reaction mix was
added to the same tube and incubated at 15°C overnight. Finally,
primary PCR reaction mix was added and the sample subjected
to 45 cycles of amplification. To minimize the chance of inad-
vertently removing the single cell, each liquid was delivered by
careful pipetting onto the wall of the tube above the other liquid
already present but without touching it. Controls for all experi-
ments included a no-cell tube containing only Ampli1 water, and
unamplified bulk DNA as a positive control. The bulk DNA was
always processed as the last sample to avoid cross-contamination.
www.frontiersin.org July 2014 | Volume 4 | Article 201 | 3
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To determine the concentration of DNA in the WGA product of
captured single cells, we used Picogreen (Life Technologies) direct
fluorescent staining according to the manufacturer’s directions. In
brief, serial dilutions of the lambda DNA stock provided in the kit
were first used to create a standard curve. A 2µl aliquot of sample
DNA was then added to 195µl of a 1:200 dilution of Picogreen
reagent in TE for a final volume of 197µl. Fluorescence was mea-
sured on a GloMax Luminometer (Promega, Madison, WI, USA)
at emission/excitation wavelengths of 490/520, and sample con-
centrations were calculated based on the standard curve. One
microliter of WGA product was then subjected to a quality control
step using the PCR-based Ampli1 QC Kit (Silicon Biosystems).
This step was always performed in the designated PCR area, not
the area dedicated for single cell WGA. After amplification, 5µl of
QC PCR product was loaded on a 1.2% agarose gel and bands for
four PCR products visualized. For those samples with at least one
visible band on the Q/C gel, PCR was performed using the Ampli1
ALK, KRAS, or PIK3CA Seq kits (Silicon Biosystems) designed to
detect mutations in the DNA libraries obtained using the Ampli1
WGA Kit. In addition, a post-PCR gel was run prior to sequenc-
ing to verify amplification of the gene of interest. If no band was
detected on the post-PCR gel, sequencing was not conducted. For
samples with a positive band on the post-PCR gel, Sanger sequenc-
ing was performed to detect known mutations in the ALK, KRAS,
and PIK3CA genes. All analyses were conducted using Sequencher
(Gene Codes Corporation, Ann Arbor, MI, USA).
PRIMER DESIGN FOR SEQUENCING OF ALK F1174L MUTATION
The Ampli1 WGA process depends on the ligation of adaptors to
DNA fragments, which are, in turn, generated by genomic diges-
tion with the restriction enzyme at TTAA sequences. Given that
the C>A transversion, resulting in the F1174L mutation of ALK,
results in an extra TTAA enzyme restriction site, our primer design
strategy for PCR with the Ampli1 ALK Seq kit had to be altered
for accurate detection of this mutation. To address this, separate
reactions were conducted to detect the wild-type allele (left intact
by restriction enzyme digestion) and the mutant allele. Given that
the mutation-containing TTAA sequence would be directly ligated
by primers for WGA, this would not leave enough space in the 5’
flanking region for addition of primers for target-specific PCR and
accurate detection of the mutation. Therefore, the PCR forward
primer was re-designed to overlap the WGA primer ligated directly
5’of the mutation site. This dictated that all reactions can be run by
reverse rather than forward sequencing. Further, the nucleotides
directly 5’ of the expected TAA codon will be detected as the
adaptor sequence rather than the expected wild-type sequence.
SHORT TANDEM REPEAT ANALYSIS
For cell lines not expressing a known point mutation at the ALK
locus, tumor cell identity was verified using STR analysis. Geno-
typing was conducted using an STR-based assay developed by
Silicon Biosystems as a multiplex PCR, compatible with Ampli1
WGA digest, with 11 loci detected across 4 fluorescence channels
with capillary electrophoresis, using as input only a 1µl aliquot
of the WGA product from single cells, generated as described
above. STR reaction mix was added to each sample as well as to
a no-amplification negative control. Samples were incubated in a
thermal cycler using the following cycles: one 15 min cycle at 94°C
and then 32 cycles with each cycle including 50 s at 94°C, 50 s at
60°C, and 1 min at 72°C. The STR call-rate was calculated by divid-
ing the number of alleles detected for each single cell by the number
of alleles expected by the STR profile obtained from genomic
DNA for the same cell line. No-amplification blanks were used
as negative controls. DNA fragment analysis was then conducted
on an Applied Biosystems 3730, and the data were analyzed using
GeneMarker software (SoftGenetics, State College, PA, USA).
RESULTS
SINGLE CELL ISOLATION
To first determine whether DEPArray-based cell isolation could be
adapted for the capture of tumor cells from patient samples, we
conducted 24 experiments using 11 different cell lines, in which
318 tumor cells were collected (Table 1). This includes 208 single
tumor cells and 110 tumor cells collected in groups of up to 50 cells.
Cell line samples were either composed of all tumor (designated
with an “A” in the Spiking ratio column of Table 1) or mixtures of
tumor cells and normal donor WBC. For some cell lines, includ-
ing SY5Y, Kelly, NB1643, and IMR5, tumor cells were first run
without mixing with WBC, and subsequent experiments were con-
ducted by titrating indicated amounts of tumor cells with WBC.
For all other experiments, either all tumor (CHLA90, SKNAS, and
NB1) or spiked tumor/WBC mixtures (LAN5, SW480, H292, and
MCF-7) were used as input.
Here, we focus on the pediatric cancer neuroblastoma, a malig-
nancy of neuro-endocrine origin, which does not express the
epithelial marker EpCAM (33). Therefore, we first sought to val-
idate cell surface tumor antigens with which tumor cells could
be specifically isolated from patient bone marrow samples. Both
the disialoganglioside GD2 and the adhesion molecule CD56 have
been shown to be widely and brightly expressed on neuroblas-
toma tumors (33, 34), however, given that CD56 is also expressed
at varying cell surface density on subsets of natural killer cells (35),
all experiments were carried out using GD2 for positive selection,
and CD45 for negative selection of cells of hematopoietic origin.
In some experiments, cells were also labeled for CD56 and antigen
expression visualized for single tumor cells also expressing GD2.
As detected by flow cytometry, the eight neuroblastoma cell lines
assayed had a wide range of GD2 expression (Figure 2A). While
there was no detectable antigen on the cell surface of CHLA90
and SKNAS, some cell lines, such as SY5Y, had overall dimmer
expression and a subset of cells that were negative for GD2, com-
pared to cell lines such as IMR5, which were uniformly bright and
positive for this cell surface molecule. Despite this range in cell
line tumor antigen expression, single tumor cells were successfully
detected and isolated in cell line spiking experiments for all six
GD2-positive neuroblastoma cell lines, and over a 5-log range of
tumor:WBC ratios (Table 1).
While some experiments were carried out using live cells as
input, some samples were either fixed or frozen prior to processing
on the DEPArray. The intention here was to mimic the conditions
that might be necessary for the preservation of a clinical sample
if immediate processing was not possible. Tumor/WBC mixtures
were labeled with antibodies to GD2, CD45, and, in some cases,
CD56, and an aliquot was injected into the DEPArray. Cells were
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Carpenter et al. Analysis of single neuroblastoma cells
Table 1 | Summary of single cells collected from cell line experiments.
Cell line Tumor
typea
Tumor antigen or
selection methodb
Mutation
detected
Number of
experiments
Spiking ratioc Single tumor
cells isolated
SY5Y N GD2 ALK (F1174L) 3 A, 1:35, 1:5,000 17
Kelly N GD2, CD56 ALK (F1174L) 4 A, A, 1:10, 1:1,000,000 43
NB1643/1643M N GD2 ALK (R1275Q) 4 A, 1:10, 1:10, 1:1,000,000 30
LAN5 N GD2 ALK (R1275Q) 2 1:10, 1:10 21
CHLA90 N Bright field ALK (F1245V) 1 A 3
IMR5 N GD2 – 4 A, A, 1:10, 1:1,000 28
SKNAS N Hoechst – 2 A, A 28
NB1 N GD2 – 1 A 3
SW480 C EGFR KRAS (G12V) 1 1:10 12
H292 L EpCAM – 1 1:10 12
MCF-7 B HER2 PIK3CA (E545K) 1 1:10 11
Totals 24 208
aN, neuroblastoma; C, colon; L, lung; B, breast.
bGD2, disialoganglioside2; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; HER2, human epidermal growth factor receptor 2.
cTumor:white blood cell ratio; A, all (100%) tumor.
then selected based on bright-field images, allowing for discrim-
ination of single versus clusters of cells (Figure 2B), and based
on dot plots of mean fluorescence intensity (MFI), much the
same as the output from a flow cytometer (Figure 2C). How-
ever, unlike with flow cytometry, on the DEPArray images can be
immediately visualized for each event (or dot), thus allowing for
on-chip, image-based phenotypic and morphologic assessment of
each cell if desired, as well as further discrimination of doublets,
non-specific binding of antibody conjugates, and other spurious
events that would likely have appeared as a single tumor cell by
flow cytometry. Representative single cell images are shown in
Figure 2C for a mixing experiment in which the GD2-dim cell
line SY5Y was mixed with WBC at a ratio of 1:35. To assess
whether single tumor cells could be isolated by means other than
cell surface staining, the GD2-negative cell lines CHLA90 and
SKNAS were isolated by bright-field (Figure 2B) and Hoechst
nuclear dye, respectively. To determine whether our approach
could be extended to other histotypes and cell surface markers,
we also conducted spiking experiments with the breast cancer cell
line MCF-7 (isolated based on HER2 labeling), colon cancer line
SW480 (EpCAM), and the non-small cell lung cancer line H292
(EGFR) (experimental parameters listed in Table 1). These results
suggest a robust and adaptable approach for single cell isolation.
CAPTURE OF VERY RARE SINGLE CELLS
Given that neuroblastoma patient blood and bone marrow sam-
ples have been shown to have a wide range of tumor involvement
(24), we next wanted to establish the sensitivity of the DEPArray
for isolation of extremely rare tumor cells. To do this, we used cell
line spiking experiments at concentrations of 1 tumor cell in 106
WBCs for two different cell lines, Kelly and NB1643M (a sub-clone
of the NB1643 cell line, which is homozygous for the R1275Q
mutation in the ALK gene). For the representative experiment
shown in Figure 2D, serial dilutions were used to generate a sam-
ple with 10 NB1643M tumor cells in 10 million WBCs. Cells were
fluorescently labeled as described above and flow cytometry-based
sorting of the entire cell population used to pre-enrich the sample
prior to loading into the DEPArray cartridge. As discussed above in
the Materials and Methods section, this was necessary for any sam-
ple with less than a 0.02% tumor cell concentration because of the
40,000 cell capacity of the cartridge. In this case, for a sample with
a tumor cell concentration of 1 in 106 WBC, the probability of hav-
ing even 1 tumor cell among all cells loaded into a cartridge with
a 40,000 cell capacity would be very low, and loading the entire 10
million cells onto multiple cartridges would have been unfeasible.
Therefore, flow cytometry-based sorting was utilized to enrich the
tumor cell population prior to loading the sample on the DEPAr-
ray. Cells were flow sorted using a sufficiently large enrichment gate
to ensure maximal capture of GD2-positive/CD45-negative cells.
This enriched fraction was then either run immediately on the
DEPArray or fixed cells were stored for up to 5 days before purifi-
cation of single cells on the DEPArray. Especially for the capture of
such rare cells, on-chip single cell imaging was essential for distin-
guishing the four intact GD2-positive/CD45-negative single cells
from high MFI debris or non-specifically stained material (dot-
plot and representative single cell images shown in Figure 2D).
This capture rate of 40% (4 cells out of the original 10 spiked)
is commensurate with cytometry- (36, 37) and dielectrophoretic-
based capture (38) of tumor cells spiked at a ratio of 1 tumor
cell in one million WBCs. Given that an average capture rate of
60% of input cells has already been demonstrated for DEPArray
(19), yields were not calculated for the rest of the experiments
described below. Taken together, these data suggest a highly spe-
cific and sensitive approach for the isolation of very rare single
tumor cells.
SINGLE CELL WGA AND TARGETED SEQUENCING
To generate sufficient starting material for genetic analysis of sin-
gle cells, Ampli1 WGA was performed. For the 179 single cell
samples, concentration of WGA product was measured by direct
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FIGURE 2 | Image-based capture of individual spiked cells. (A) Cell
surface GD2 expression was measured by flow cytometry for the eight
neuroblastoma cell lines used for isolation of single cells (and listed at right),
as compared to negative control WBCs and isotype control. (B) WBCs and the
GD2-dim neuroblastoma cell line SY5Y were mixed at a tumor:WBC ratio of
1:35, pre-labeled with GD2-PE, CD45-FITC, and Hoechst nuclear dye, then
injected into the DEPArray. Shown are bright-field images of (i) a single tumor
cell (bar depicts 10µm) and (ii) a cluster of two cells. In (C), a scatter plot of
GD2-PE and CD45-FITC mean fluorescence intensity (MFI) is shown as well
as cell images, including on the left-hand side of the dot-plot (i) an image of a
single tumor cell and (ii) a single WBC, and on the right-hand side (iii) a
heterogeneous cluster, (iv) a homogeneous cluster, and (v) a spurious event.
(D) NB1643M cells and normal donor WBCs were mixed at a ratio of
1:1,000,000 and stained with GD2-PE and CD45-FITC, in this representative
experiment. The sample was pre-enriched using FACSAria-based sorting, and
the enriched fraction placed into the DEPArray cartridge. Shown are a scatter
plot of GD2-PE and CD45-FITC MFI, as well as images of (i–iv) intact tumor
cells, (v and vi) WBCs, and (vii–ix) debris and false-positive events.
fluorescent staining (including single cells isolated from cell lines
as well as the patient samples described in more detail below),
and the mean WGA product concentration was 38.44 ng/µl in a
50µl volume for a total WGA product of 1.922µg (± 0.0610µg,
range 0.243–4.048 g) per sample. To assess the effect of sample
preparation on the amount of WGA product, we compared results
for live (n= 58), fixed (n= 95), or frozen/thawed (frozen after
capture, stored at -80°C, then thawed prior to WGA; n= 26) cells,
and found no difference in yield (p= 0.1530 for live versus fixed,
p= 0.1548 for live versus frozen/thawed, p= 0.3756 for fixed ver-
sus frozen/thawed; Figure 3A). Similarly, and comparing among
fixed samples only, whether the sample was pre-enriched by FACS
(n= 55) or not (n= 40) had no effect on WGA yield (p= 0.2890;
Figure 3B). To assess WGA product quality, PCR for four control
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FIGURE 3 | Whole genome amplification and targeted sequencing of
single cells. Single cells were isolated by DEPArray, DNA extracted, Ampli1
WGA performed, and the DNA concentration of each sample measured by
Picogreen. (A) The mean WGA yield in micrograms of DNA for the 50µl
elution volume for n=58 live (unfixed) single cells, n=95 fixed single cells,
and n=26 frozen/thawed single cells; and (B) n=40 single cells from
unenriched samples (left bar) and n=55 single cells (right bar) from samples
that had been pre-enriched by flow sorting prior to single cell capture on the
DEPArray. Included in this analysis are single cells isolated from spiked cell
lines as well as patient samples described in the text. For the data shown in
(B), all cells were fixed. (C) A 1:10 mix of NB1643 cells and WBCs was
pre-labeled, single cells collected by DEPArray, DNA extracted, and WGA
performed. WGA product was subjected to a quality control step in which
bands for 4 housekeeping genes were visualized, as shown for 12 single
heterozygous NB1643 tumor cells (columns 1–12), 3 WBCs (columns 13–15),
a no-cell “blank” (B), a water control (H), and positive control genomic
NB1643 DNA (+). Detection of the mutant allele is denoted by “+” in row
M, and detection of the wild-type allele in Row WT. (D) WGA products
with one or more bands were submitted for targeted sequencing at the ALK
locus. Shown are chromatograms depicting the G>A transition (R1275Q)
for NB1643 cell #3 (top) and wild-type sequence for WBC#13 (below).
(Continued)
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FIGURE 3 | Continued
(E) NB1643M tumor cells, homozygous for the R1275Q mutation, were
spiked into WBCs at a 1:1,000,000 ratio, and single cells were captured.
Shown is the Q/C blot for the four tumor cells and two WBCs isolated
(corresponding dot-plot and single cell images shown in Figure 2D), with
sequencing results below the blot and (F) the chromatogram for tumor cell #3
depicting the known homozygous G>A transition (top) and for WBC#6
showing wild-type sequence (bottom). (G) A 1:10 mix of Kelly cells and WBCs
was frozen at -80°C, then thawed and stained before DEPArray-based capture
and WGA. Shown is the Q/C gel for 12 single Kelly cells, 3 WBCs, a water
control (H), and genomic Kelly DNA (+). Detection of the mutant and
wild-type alleles is depicted below. (H) Chromatograms for tumor cell #2
depicting the mutant allele (top panel) and the wild-type allele (bottom panel).
As described in the Materials and Methods section, for cell lines such as Kelly
expressing the heterozygous F1174L mutation, sequencing of the mutant and
wild-type alleles are conducted in separate reactions.
sequences was performed. As shown in Figure 3C for a spiking
experiment using live NB1643 cells, four bands were detected on
the Q/C gel for 12 of the 15 single cells. No bands were detected
in this or any other experiment for the no-cell blank collected
from the DEPArray cartridge. Only cells with one or more visible
bands were selected for further analysis, since the absence of any
bands suggests that either the cell was lost subsequent to DEPArray
capture or the WGA reaction incomplete. To verify tumor versus
WBC identity, WGA products for the 12 cells with visible bands
were amplified using primers specific for the known heterozygous
R1275Q ALK mutation, and targeted sequencing performed. As
shown in the chromatograms in Figure 3D, the expected muta-
tion (top) and wild-type sequence (bottom) were detected in a
tumor cell and WBC, respectively. Targeted sequencing results for
all cells are shown below the gel in Figure 3C, and indicate that
the expected mutant allele was not detected in tumor cells #11 and
12. This could be due to cell to cell heterogeneity, allelic dropout
(ADO), or a WBC having been isolated rather than a tumor cell.
No mutant allele was detected in either of the WBCs sequenced
here, or for the 161 WBCs isolated across all experiments described
in this report. To determine whether this approach could be used
for genetic analysis of very rare cells, we analyzed single cells cap-
tured subsequent to FACS-based pre-enrichment of a sample with
tumor cell concentration of 1:1,000,000 (cell images and dot-plot
shown in Figure 2D). For this experiment, the NB1643M cell line
expressing a homozygous ALK mutation was used, and Q/C analy-
sis of the WGA products resulted in one or more bands for four
of the six captured cells (two tumor and two WBCs; Figure 3E).
Sequencing results shown in Figure 3E indicate detection of the
expected mutation in the two tumor cells and wild-type sequence
in the two WBCs (representative chromatograms in Figure 3F).
To further explore the effect of freezing/thawing cells, we con-
ducted experiments in which cell lines were spiked into WBCs,
half the mixture stained and immediately run on the DEPAr-
ray, whole genome amplified and sequenced, and the other half
frozen at -80°C for several weeks before further processing. As
shown on the representative Q/C blot for the Kelly neuroblastoma
cell line in Figure 3G, one or more bands were detected on the
Q/C gel for 14 out of 15 single cells, the mutant allele for this
heterozygous cell line detected in 10 out of 11 tumor cells, and
the wild-type allele detected in all cells sequenced. Representative
chromatograms shown in Figure 3H depict the known F1174L
mutant allele (top) and the wild-type allele (bottom) for tumor
cell #2 run in separate reactions (as described in the Materials and
Methods section). Moreover, there was no evidence of antigen
degradation or change in staining pattern when comparing fresh
with frozen/thawed single cell images (representative single cells
shown in Figure A1 in Supplementary Material).
Verification of tumor cell identity for single cells isolated by
DEPArray from spiking experiments using the SW480 colon car-
cinoma cell line and the MCF-7 breast cancer cell line was achieved
by sequencing of the known KRAS (G12V) and PIK3CA (E545K)
mutations, respectively (Table 1). For neuroblastoma cell lines
not known to harbor an ALK mutation, we used genotyping of
short tandem repeats (STRs) at 11 loci. As shown for two loci
in Figure A2 in Supplementary Material, the genotype of single
tumor cells was consistent with that of unamplified genomic DNA
from the same cell line but distinct from the WBC isolated from
the same spiking experiment, thus demonstrating an additional
means of validating tumor cell identity.
Finally, to more comprehensively assess the effect of cell prepa-
ration on sequencing reliability, we compared results for 240 single
cells (208 cell line and 32 WBCs), including fixed (n= 40), live
(n= 171), or freeze/thawed (n= 29) cells (Figure 4). Sequenc-
ing was conducted and ADO rate was calculated only for cells for
which one or more bands were detected on the Q/C gel. Overall
sequencing success, defined as the percentage of single cell WGA
products for which a sequence result was obtained, was 91.5%,
and ranged from 89.6% for live, 93.3% for fixed, and 100.0%
for thawed cells. The ADO rate for tumor cells (the percentage
of known alleles not detected) was 7.0%, with live and thawed
cells having dropout rates of 5.8 and 4.8%, respectively. Fixed
cells had a higher ADO at 15.0%, and an even higher propor-
tion (42.5%) of cells with only one band detected on the Q/C
gel. Given the likely fixation-induced DNA cross-linking, these
results are not unexpected. In fact, three of the four Q/C PCR tar-
gets are located in very large amplicons (>1100 base-pairs, above
99th percentile of the size distribution of WGA digest) and are
more difficult to amplify. The ADO rate for smaller post-WGA
fragments (comprising most of the WGA library at 100–200 base-
pairs) is typically lower. To determine the relationship between
number of Q/C bands and sequencing success and ADO, we tabu-
lated Q/C results by cell preparation method (Figure 4). Although
the overall percentage of single cells (tumor and WBCs) with 2–
4 Q/C bands varies widely depending on cell preparation (fixed
32.5%, live 73.7%, thawed 89.6%, and overall 68.8%), the per-
centage with one or more varied less (fixed 75.0%, live 84.2%,
thawed 89.6%, and overall 83.3%). Cells with 2–4 bands had a
sequencing success rate of 94.5%, and an ADO of 4.8%, whereas
cells with 1 band had lesser results, with sequencing success of
72.2% and ADO of 19.0%. These results suggest that although
sequencing reliability and accuracy are higher for cells with 2–4
bands on the Q/C gel, the vast majority of cells with at least 1
Q/C band will generate accurate sequence data. Taken together,
these results demonstrate a reliable approach for the WGA and
sequencing of single tumor cells, and that multiple approaches
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FIGURE 4 | Sequencing success and allelic dropout (ADO) rate. Two
hundred forty single cells, including tumor cells (n=208) and WBCs
(n=32), were collected from spiking experiments and subjected to WGA.
Among the 240 single cells, 40 fixed, 171 live, and 29 thawed cells were
analyzed for the number of bands detected on the post-WGA Q/C gel. The
height of each bar represents the percentage of cells with 2–4 (dark grey),
1 (light grey), or 0 bands (white) on the Q/C gel. Shown at right and below
the graph are the sequencing success rates for all 240 tumor cells and
WBCs by category, as well as the allelic dropout rate for the 110 tumor
cells sequenced.
can be used for preserving samples that cannot be immediately
processed.
CAPTURE AND GENETIC ANALYSIS OF SINGLE CELLS FROM PATIENT
SAMPLES
To assess the feasibility of clinical application of single tumor
cell capture and genetic analysis, we next applied our approach
to 10 bone marrow samples of patients. As outlined in Table 2,
this includes seven samples with known ALK status in the corre-
sponding primary tumor (as detected by our Molecular Genetics
Laboratory), and three samples for which ALK status of the pri-
mary tumor was unknown. As also detailed in Table 2, for patient
9, two different bone marrow samples were analyzed and are listed
as samples 9a and 9b. The post-Ficoll fractions of all patient sam-
ples were fixed before processing, and all together, 178 total single
cells (144 DTCs and 34 WBCs) were collected from these 10 bone
marrow samples of patient. To assess the level of tumor involve-
ment prior to running the sample on the DEPArray, each sample
was stained for GD2, CD56, and CD45, and an aliquot of cells
run on the flow cytometer (see FACS results for representative
patient CHOP7 in Figure 5A). For this and all other patients with
a percentage of GD2-positive tumor cells at or below our prede-
termined threshold of 0.02%, we next conducted pre-enrichment
on the FACSAria by setting a wide collection gate (depicted by
P2 in Figure 5B), and then injected the enriched product into
the DEPArray cartridge and collected 15 single tumor cells (two
representative images shown in Figure 5C; no WBCs were col-
lected in this experiment). Consistent with the flow cytometry
results in Figure 5A, single cell images of all tumor cells collected
showed brightly expressed GD2 but there was heterogeneity of
CD56 expression with some cells more strongly expressing CD56
(Figure 5C, top row) and others expressing the antigen more dimly
(Figure 5C, bottom row). All isolated tumor cells had one or
more bands on the Q/C gel and were, therefore, sequenced to ver-
ify presence of the heterozygous F1174L mutation that had been
detected in the patient’s primary tumor. Indeed, the mutant allele
was detected in all 15 cells and the wild-type allele in 13 out of
15 cells, implying that two tumor cells were either homozygous
for the mutant allele or had suffered from ADO of the wild-
type allele during WGA (Figure 5D). Shown in Figure 5E are the
chromatograms for tumor cell #8 including the wild-type allele
(top) and the mutant allele (bottom) run in separate reactions as
described above. These results demonstrate concordance between
the targeted sequencing results for the solid tumor and DTCs from
patient CHOP7. Despite the wide range in tumor involvement for
all patients studied (0.01–80.0%; Table 2), similar concordance
was shown for all patients with known primary tumor ALK status.
Overall, we found that patient marrow samples ran without
complication on the DEPArray apparatus. Based on analysis of
the diameter of patient single cells recovered by DEPArray, we
determined that there was considerable overlap between the 56
GD2+ tumor cells and 22 WBCs measured (Figure 5F), suggest-
ing that commonly used cell size-based filtration methods would
be unlikely to provide sufficient pre-enrichment of disseminated
neuroblastoma tumor cells. As previously discussed (and displayed
in Figures 3A,B), the overall mean WGA yield for 95 single cells
that had been fixed prior to WGA was 1.884+ 0.8145µg. However,
that yield varied considerably between WGA products for single
cells from cell lines and patient samples, with the WGA yield for
64 patient single cells (1.629+ 0.09011µg; all cells fixed) being
significantly lower than that seen for 31 fixed single cells from
cell line experiments (2.409+ 0.1349µg, p< 0.0001; Figure 5G).
Nevertheless, the lower yield from patient cells was still sufficient
for multiple downstream analyses. When aliquots of WGA product
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Table 2 | Summary of single DTCs collected from neuroblastoma patient bone marrow samples.
Patient FACS-based
pre-enrichment
Bone marrow %
tumora
Primary tumor
ALK status
DTC ALK
status
Single tumor
cells isolated
WBC isolated
CHOP1 No 0.12 Unknown – 5 4
CHOP2 No 19.00 Unknown – 6 10
CHOP4 No 0.11 Unknown – 9 0
CHOP6 Yes 0.01 WT WT 15 0
CHOP7 Yes 0.02 F1174L F1174L 15 0
CHOP8 No 4.00 F1174L F1174L 22 3
CHOP9a Yes N/A Y1278S Y1278S 12 2
CHOP9b No 80.00 Y1278S Y1278S 12 3
CHOP10 No 1.4 WT WT 24 6
CHOP11 No 40.00 WT WT 24 6
Totals 144 34
aAs measured by flow cytometry.
were run on a Q/C gel, one or more bands were detected in 68.5%
of patient single cells, which was slightly below the 75.0% achieved
for fixed single cells from cell line spiking experiments. For the cells
with one or more Q/C bands, a sequencing result was obtained for
87.7% of patient and 93.3% of fixed spiked cell line cells. ADO rates
were also similar with patient cells having a slightly lower rate of
12.7% as compared to spiked cell line cells at 15.0% (Table 3).
These data suggest a robust and highly sensitive approach for cap-
ture of single tumor cells from neuroblastoma patient samples,
and detection of known point mutations.
DISCUSSION
We have presented here a reliable and adaptable approach for the
capture and downstream analysis of single tumor cells. Routine
sampling and interrogation of the circulating and disseminated
tumor compartments facilitate important basic science and trans-
lational medicine goals. In order to realize the true benefits of
personalized cancer therapy, molecular profiling of patient tumors
must extend beyond limited sampling of bulk primary tumor
tissue. Repeated invasive procedures, however, are not an accept-
able means of addressing this need and, for many cancer patients
with advanced disease, access to the primary tumor is impossi-
ble. Indeed, for children suffering from neuroblastoma, the cancer
focused on in this study, primary tumor samples are often difficult
or impossible to obtain, due to the tumor’s paraspinal and/or bony
location. Curative therapies have yet to be identified in the relapse
setting for neuroblastoma patients, underscoring the need for new
approaches to molecular characterization of the tumor that will
lead to more effective therapeutic strategies. Limited access to
primary tumor makes it challenging to ascertain the status of mol-
ecular markers such as point mutations in ALK. While the most
common ALK variants (R1275Q and F1174L) in neuroblastoma
confer differential sensitivity to the kinase inhibitor crizotinib (39),
a compound with promising results in a recent Phase I trial (31),
identifying candidate patients for this targeted therapy and deter-
mining their mutation status is often impossible when primary
tumor tissue is unavailable. Here, we have shown an approach for
the capture of very rare cells from starting populations as low as
1 in one million cells. Using this approach, we were able to iso-
late DTCs from marrow samples with a tumor cell concentration
as low as 0.01%, and demonstrate concordance for ALK status
between primary tumor and DTCs for all patients for whom sta-
tus of the primary tumor had been ascertained. This suggests an
approach that can be adapted to provide crucial clinically relevant
information for the stratification of neuroblastoma patients onto
therapy with an ALK inhibitor.
While several groups have demonstrated the feasibility of
accessing and analyzing circulating tumor (3, 6, 40, 41), current
approaches are largely limited by their reliance on EpCAM as a
cell surface marker with which to differentiate tumor from WBCs
in the blood or marrow. More recently developed approaches
have incorporated additional markers for CTC/DTC detection,
including markers for the detection of tumor cells that have under-
gone EMT, and yielding improved sensitivity and the detection of
EpCAM-negative subsets of CTC/DTCs (6, 40, 42). For example,
multiparametric flow-based sorting, including labeling of multiple
cell surface markers on breast cancer CTCs, led to the identifica-
tion of a possible signature of brain metastasis among EpCAM-
negative cells (40). In addition, Yu and colleagues recently used
labeling with multiple antibodies and a microfluidic approach
to isolate circulating breast tumor cells from patient blood and
showed considerable variability in epithelial and mesenchymal
characteristics across different histological subtypes of breast can-
cer (6). However, it has also become increasingly clear that human
cancers demonstrate complex subclonal heterogeneity, suggesting
that CTC/DTCs will also be heterogeneous in terms of potentially
targetable genetic alterations. Using current approaches to iso-
late CTC/DTCs, enriched cells cannot be individually isolated for
downstream genetic analysis. The results we report here demon-
strate proof of principle that individual tumor cells can now be
captured for downstream genetic analysis.
Although use of the DEPArray for CTC isolation from patient
blood samples has been reported (18, 19), the work described here
provides a comprehensive method for microfluidic-based isola-
tion and genetic analysis of single DTCs from patient marrow
samples. DTCs from neuroblastoma patient samples were isolated
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FIGURE 5 | Isolation and targeted sequencing of rare individual
patient DTC. (A) The post-Ficoll fraction for a bone marrow sample from
patient CHOP7 was fixed, stained for CD45, CD56, and GD2, and an
aliquot was analyzed by flow cytometry. Given that only 0.02% of cells
were determined to be GD2-positive, (B) pre-enrichment was conducted
on the FACSAria using the wide P2 gate shown. (C) Representative
images of staining for GD2 (first column; bar depicts 10µm), CD56 (middle
column), and CD45 (right column) are shown for single cells #15 (top row)
and #7 (bottom row). (D) A gel for the quality control panel of four
housekeeping genes is shown with a “+” below depicting detection of
either the mutant allele (top row labeled “M” or the wild-type allele
bottom row labeled “WT”). (E) The chromatogram of the wild-type (top)
and mutant allele (bottom) for cell #8. (F) Diameter of patient cells, as
measured for 56 tumor cells and 22 WBCs while in solution on the
DEPArray chip. (G) Bone marrow samples of patients were processed as
described above and direct fluorescent staining used to measure the DNA
concentration of WGA product from single cells. Mean WGA yield for
n=64 patient single cells is shown in comparison to the yield for n=31
single tumor cells from cell line spiking experiments. In this analysis, all
patient and cell line cells were fixed.
based on expression of the cell surface marker GD2, while spiked
cell line tumor cells were detected and captured by labeling for
GD2, HER2 (breast), EGFR (NSCLC), and EpCAM (colon). In
an effort to extend our approach to additional histotypes, we are
currently adapting the above described DTC-isolation protocols
for breast cancer patient marrow samples, and work is ongoing
to apply GD2-based isolation approaches to the blood samples of
patients with melanoma and small cell lung cancer (SCLC) as both
tumors have been shown to express this cell surface marker (43,
44). We have also demonstrated the feasibility of both fixation and
freezing as approaches to temporally disassociate the acquisition
and processing of patient samples, a necessary component for the
routine analysis of clinical samples. We are currently working to
enhance the sensitivity of detecting CTC/DTCs of epithelial origin
before and after EMT by adding epithelial markers such as EpCAM
and E-Cadherin and mesenchymal markers including vimentin
and N-Cadherin. Use of multiple markers will enhance the yield
of captured CTC/DTCs from among a heterogeneous population,
with the goal of eventually extending this platform to disease mon-
itoring and the detection of minimal residual disease, especially
for patients in radiographic remission. Importantly, such adapta-
tion is easily achievable with the DEPArray as the combination of
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Table 3 | WGA and sequencing of fixed single cells.
Type of
sample
Cells with≥1
Q/C banda (%)
Cells successfully
sequenceda (%)
Allelic dropoutb
(%)
Patient 68.5 87.7 12.7
Cell line 75.0 93.3 15.0
aTumor cells and WBCs.
bTumor cells only.
staining antibodies can be adjusted for each sample or histotype
without the re-fabrication or re-coating of the internal structure
of the chip.
Until recently, the downstream analysis of patient samples has
largely focused on endpoints that technology could afford, namely
genomic profiling of homogenized primary tumor samples with
little regard to intratumoral heterogeneity. Major technological
challenges have included the reliable amplification and analysis
of single cell DNAs, with the 6–7 pg of genomic DNA typically
extracted from a single cell (45) being insufficient for most down-
stream analysis. Introduction of WGA artifacts and DNA conta-
mination during single cell DNA amplification have also impeded
progress. These challenges were addressed in recent reports in
which single cell sequencing was shown to provide unique insights
into a limited number of cancer genomes (46–48). Here, we
provide comprehensive quantification of the accuracy and suc-
cess rate of each step in a detailed approach for genetic analysis
of single tumor cells. To generate sufficient DNA for targeted
sequencing of isolated single cells, we used Ampli1 global ampli-
fication based on restriction enzyme digest, adaptor ligation, and
PCR amplification. Among cell lines, WGA and targeted sequenc-
ing were conducted at five loci [KRAS(G12V), PIK3CA(E545K),
and ALK(F1174L, R1275Q, and F1245V)], suggesting that this
approach could be extended to the detection of point mutations
in multiple genes, including those associated with resistance to
kinase inhibitors and other targeted therapies. Indeed, the F1174L
point mutation detected here in neuroblastoma patients prior to
therapy has also been identified as a resistance mechanism in a
patient with an inflammatory myofibroblastic tumor who was
treated with Crizotinib (49).The fidelity of the WGA process as
measured by ADO rate was 5.8% for live single cells, a rate that is
commensurate with recently published studies (46, 50). Although
the ADO for patient samples was higher at 12.7%, all patient sam-
ples were fixed, and this rate for patient samples is comparable
to the 15.0% ADO measured for spiked fixed cells. Importantly,
these ADO rates were calculated only for cells for which one or
more bands were detected on the Q/C gel of four housekeep-
ing genes. No mutant allele was detected in any of the 161 WBC
sequenced, suggesting a lack of cross-contamination between sam-
ples. Sequencing of single cells isolated from the bone marrow
of patients whose primary tumors harbored a heterozygous ALK
mutation sometimes resulted in either a homozygous wild-type or
homozygous mutant call. Although this suggests the possibility of
cell to cell heterogeneity at this locus, more samples would have to
be studied to determine whether this is true heterogeneity. While
unlikely, a homozygous wild-type call could have resulted from
isolation of extremely rare GD2-positive CD45-negative bone
marrow mesenchymal stem cells (51). Finally, both false-negative
and false-positive calls may simply be reflective of the underlying
ADO rate of the WGA process. Nevertheless, reductions in ADO
rate resulting from rapid advancement in single cell genomic tech-
nology (46, 47, 52), coupled with DEPArray-based tumor cell
isolation promise the routine and accurate detection of clinically
relevant and therapeutically targetable genetic aberrations in a
non-invasive manor. As efforts continue to streamline and shorten
processing times for single cell isolation and WGA, performing
such tests in a clinical setting will become more achievable.
Here, we have used neuroblastoma as a model for the study
of disseminated tumor cells. Our development of a pipeline for
sequence level analysis of individual disseminated metastatic can-
cer cells isolated from patient samples is but the first step in
realizing the basic science and clinical benefits of studying this
compartment. Ultimately, a comprehensive genome-wide under-
standing of the genetic markers and drivers of metastasis will
require next generation, rather than targeted, sequencing of single
or few cells. Development of clinical tests will likely require simul-
taneous interrogation of a panel of genes in order to be truly ther-
apeutically meaningful. Addressing these challenges and devel-
oping both research- and clinical-lab approaches to the study of
CTC/DTCs will lead to important advancements in the treatment
of cancer.
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